<VariationArchive VariationID="2055134" VariationName="NM_001378454.1(ALMS1):c.1785dup (p.Glu596Ter)" VariationType="Duplication" Accession="VCV002055134" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2109134" VariationID="2055134">
      <GeneList>
        <Gene Symbol="ALMS1" FullName="ALMS1 centrosome and basal body associated protein" GeneID="7840" HGNC_ID="HGNC:428" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="73385758" stop="73609919" display_start="73385758" display_stop="73609919" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791766.1" start="55253" stop="279417" display_start="55253" display_stop="279417" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="73612885" stop="73837045" display_start="73612885" display_stop="73837045" Strand="+" />
          </Location>
          <OMIM>606844</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_001378454.1(ALMS1):c.1785dup (p.Glu596Ter)</Name>
      <CanonicalSPDI>NC_000002.12:73448311:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>2p13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="73448311" stop="73448312" display_start="73448311" display_stop="73448312" variantLength="1" positionVCF="73448311" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="73675438" stop="73675439" display_start="73675438" display_stop="73675439" variantLength="1" positionVCF="73675438" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
      </Location>
      <ProteinChange>E596*</ProteinChange>
      <ProteinChange>E597*</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.73675439dup" Assembly="GRCh37">
            <Expression>NC_000002.11:g.73675439dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.73448312dup" Assembly="GRCh38">
            <Expression>NC_000002.12:g.73448312dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011690.1" sequenceAccession="NG_011690" sequenceVersion="1" change="g.67560dup">
            <Expression>NG_011690.1:g.67560dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001378454.1" sequenceAccession="NM_001378454" sequenceVersion="1" change="c.1785dup" MANESelect="true">
            <Expression>NM_001378454.1:c.1785dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001365383.1" sequenceAccession="NP_001365383" sequenceVersion="1" change="p.Glu596Ter">
            <Expression>NP_001365383.1:p.Glu596Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_015120.4" sequenceAccession="NM_015120" sequenceVersion="4" change="c.1788dup">
            <Expression>NM_015120.4:c.1788dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_055935.4" sequenceAccession="NP_055935" sequenceVersion="4" change="p.Glu597Ter">
            <Expression>NP_055935.4:p.Glu597Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_741" sequenceAccession="LRG_741">
            <Expression>LRG_741:g.67560dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_741t1" sequenceAccession="LRG_741t1">
            <Expression>LRG_741t1:c.1788dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_741p1" sequenceAccession="LRG_741p1" change="p.Glu597Ter">
            <Expression>LRG_741p1:p.Glu597Ter</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001378454.1(ALMS1):c.1785dup (p.Glu596Ter) AND Alstrom syndrome" Accession="RCV002909969" Version="2">
        <ClassifiedConditionList TraitSetID="1087">
          <ClassifiedCondition DB="MedGen" ID="C0268425">Alstrom syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-23" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-12-23" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17594715</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1087" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="207" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Alstrom syndrome</ElementValue>
                <XRef ID="Alstrom+Syndrome/341" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008763" DB="MONDO" />
                <XRef ID="63702009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alstrom's syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ALMS</ElementValue>
                <XRef Type="MIM" ID="203800" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ALSS</ElementValue>
                <XRef Type="MIM" ID="203800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Alstr√∂m syndrome is characterized by cone-rod dystrophy, obesity, progressive bilateral sensorineural hearing impairment, acute infantile-onset cardiomyopathy and/or adolescent- or adult-onset restrictive cardiomyopathy, insulin resistance / type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and chronic progressive kidney disease. Cone-rod dystrophy presents as progressive visual impairment, photophobia, and nystagmus usually starting between birth and age 15 months. Many individuals lose all perception of light by the end of the second decade, but a minority retain the ability to read large print into the third decade. Children usually have normal birth weight but develop truncal obesity during their first year. Sensorineural hearing loss presents in the first decade in as many as 70% of individuals and may progress to the severe or moderately severe range (40-70 db) by the end of the first to second decade. Insulin resistance is typically accompanied by the skin changes of acanthosis nigricans, and proceeds to T2DM in the majority by the third decade. Nearly all demonstrate hypertriglyceridemia. Other findings can include endocrine abnormalities (hypothyroidism, hypogonadotropic hypogonadism in males, and hyperandrogenism in females), urologic dysfunction / detrusor instability, progressive decrease in renal function, and hepatic disease (ranging from elevated transaminases to steatohepatitis/NAFLD). Approximately 20% of affected individuals have delay in early developmental milestones, most commonly in gross and fine motor skills. About 30% have a learning disability. Cognitive impairment (IQ &lt;70) is very rare. Wide clinical variability is observed among affected individuals, even within the same family.</Attribute>
                <XRef ID="NBK1267" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5787" />
                <XRef ID="5787" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301444</ID>
                <ID Source="BookShelf">NBK1267</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">21522186</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES/PES/ESE, 2017">
                <ID Source="PubMed">28359099</ID>
                <ID Source="pmc">6283429</ID>
              </Citation>
              <XRef ID="64" DB="Orphanet" />
              <XRef ID="C0268425" DB="MedGen" />
              <XRef ID="MONDO:0008763" DB="MONDO" />
              <XRef Type="MIM" ID="203800" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5953613" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="15479659|MedGen:C0268425" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003265415" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17594715</ID>
          </Citation>
          <Comment>This variant has not been reported in the literature in individuals affected with ALMS1-related conditions. For these reasons, this variant has been classified as Pathogenic. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu597*) in the ALMS1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALMS1 are known to be pathogenic (PMID: 17594715).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ALMS1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.73675438_73675439insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268425" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5953613" TraitType="Disease" MappingType="XRef" MappingValue="C0268425" MappingRef="MedGen">
        <MedGen CUI="C0268425" Name="Alstrom syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

